Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
The medical community calls the movement from severe to mild disease and from mild to normal health, 'relieving symptoms', and the interventions that cause such movement, drugs, medications, or therapies. The alternative community calls the movement from normal health to superior health, 'boosting health' (or boosting the immune system, or improving your sex drive, or boosting any another well functioning physiological system), and the interventions that cause such movement, natural remedies, dietary supplements, complementary treatments, etc. In general, these interventions aim to achieve superior performance of a normal human body. Of course, boosting the body's normal performance improves many of its capabilities, such as higher resistance to diseases, faster recovery from fatigue, better mental concentration, etc. Each movement presents different objectives. Relieving symptoms represents the ability of an intervention to reduce the frequency, duration, and severity of a disease. In contrast, boosting health represents the ability of an intervention to increase the frequency, duration, and quality of a person's health. In the current study, the investigators would like to measure the changes in health-related complaints by analyzing charts of individuals, who are infected with latent virus, and who have used Gene-Eden-VIR/Novirin.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Herpes Simplex Virus Infection | Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months |
| |
| Human Papillomavirus Infection | Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months |
| |
| Epstein-Barr Virus Infection | Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months |
| |
| Cytomegalovirus Infection | Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months |
| |
| Varicella Zoster Virus Infection | Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gene-Eden-VIR/Novirin | Dietary Supplement |
|
| Measure | Description | Time Frame |
|---|---|---|
| frequency of symptoms | one year | |
| duration of symptoms | one year |
| Measure | Description | Time Frame |
|---|---|---|
| time to first recurrence | one year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Men and women ages greater than 18 years old
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The Center for the Biology of Chronic Disease | Valley Cottage | New York | 10989 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27766602 | Derived | Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006561 | Herpes Simplex |
| D020031 | Epstein-Barr Virus Infections |
| D000073618 | Varicella Zoster Virus Infection |
| D003586 | Cytomegalovirus Infections |
| ID | Term |
|---|---|
| D006566 | Herpesviridae Infections |
| D004266 | DNA Virus Infections |
| D014777 | Virus Diseases |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| C000616902 | Gene-Eden-VIR |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D017193 |
| Skin Diseases, Viral |
| D012874 | Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D014412 | Tumor Virus Infections |